ANI Pharmaceuticals (NASDAQ:ANIP) Director Matthew J. Leonard Sells 6,937 Shares

Key Points

• Director Matthew J. Leonard sold 6,937 shares of ANI Pharmaceuticals at an average price of $88.17, decreasing his ownership by 42.48%.
• ANI Pharmaceuticals reported $1.80 EPS in the latest quarter, surpassing analysts' expectations and achieving a 53.2% year-over-year revenue increase.
• Analysts have set target prices for ANI Pharmaceuticals, with an average price of $84.75 and several firms maintaining or upgrading their ratings to "buy" or "strong-buy."

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) Director Matthew J. Leonard sold 6,937 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $88.17, for a total value of $611,635.29. Following the completion of the sale, the director directly owned 9,392 shares of the company's stock, valued at approximately $828,092.64. This represents a 42.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

ANI Pharmaceuticals Stock Down 0.1%

NASDAQ ANIP traded down $0.13 during trading on Friday, hitting $91.01. The company's stock had a trading volume of 432,200 shares, compared to its average volume of 737,724. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The company has a market cap of $1.97 billion, a PE ratio of -118.19 and a beta of 0.61. The business's 50 day simple moving average is $70.63 and its 200-day simple moving average is $65.95. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $92.53.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company's quarterly revenue was up 53.2% on a year-over-year basis. During the same quarter last year, the company earned $1.02 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on ANIP. Truist Financial raised their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, August 11th. Guggenheim reissued a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright reissued a "buy" rating and issued a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday. Finally, Piper Sandler restated an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $84.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Newbridge Financial Services Group Inc. raised its position in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after acquiring an additional 400 shares in the last quarter. State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Public Sector Pension Investment Board raised its position in ANI Pharmaceuticals by 10.2% during the second quarter. Public Sector Pension Investment Board now owns 58,053 shares of the specialty pharmaceutical company's stock valued at $3,788,000 after acquiring an additional 5,385 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock valued at $1,267,000 after acquiring an additional 198 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in ANI Pharmaceuticals by 542.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company's stock valued at $113,000 after acquiring an additional 1,458 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.